Free access to the latest research

 

Welcome to the Obstetrics Resource Centre, with free access to the latest research in the field. 
All content is independently selected by the Editors, Professor James O. Drife from Leeds, UK, and Professor Jim Thornton from Nottingham. The Obstetrics Resource Centre provides you with original articles, reviews, selected must-reads, lectures and a congress planner.

 

From the other journals

  • Editor’s comment: Prof. Jim Thornton: Induction of labour for suspected macrosomia

    A large trial from France and Switzerland has shown that a polic yog labour induction between 37 and 39 weeks for suspected macosomia reduces shoulder dystocia, birth trauma and does not increase caesarean delivery rates.

    Boulvain, M et al. for the Groupe de Recherche en Obstétrique et Gynécologie (GROG) Induction of labour versus expectant management for large-for-date fetuses: a randomised controlled trial.  Lancet. Published online 8 April 2015

    Induction of labour for suspected macrosomia

  • Editor’s comment: Prof. Jim Thornton: Timed delivery for fetal growth restriction

    The main results for the TRUFFLE trial, comparing three fetal monitoring regimes for severe early onset fetal growth restriction, show no major differences between the groups. Among survivors neurodevelopmental outcomes were better among babies delivered after late venous Doppler changes compared with those delivered after early changes.

    Lees C et al, for the TRUFFLE study group (2015) Two year neurodevelopmental and intermediate perinatal outcomes in infants with very preterm fetal growth restriction (TRUFFLE): a randomised trial. Volume 385, Issue 9983, 30 May–5 June 2015, Pages 2162–2172

    Timed delivery for fetal growth restriction

Pages

Selected EJOG Papers

  • Editor’s comment: Prof. James Drife: Pregnancy after placenta accreta
    Placenta accreta results in hysterectomy in about 25% of cases, but in the others conservative treatment is successful. If a woman chooses to have another pregnancy, what are the risks? A recent study found a high risk of recurrent placenta accreta and a fourfold increase in risk of postpartum haemorrhage compared to a control group. This study reports similar findings. Nevertheless a history of placenta accreta was not a risk factor for overall perinatal mortality and was associated with a lower risk of hypertensive disorder in subsequent pregnancy.

    A prior placenta accreta is an independent risk factor for post-partum hemorrhage in subsequent gestations

    Adi Vinograd, Tamar Wainstock, Moshe Mazor, Salvatore Andrea Mastrolia, Ruthy Beer-Weisel, Vered Klaitman, Doron Dukler, Batel Hamou, Neta Benshalom-Tirosh, Ofir Vinograd, Offer Erez

    European Journal of Obstetrics & Gynecology and Reproductive Biology, pages 20 - 24

  • Editor’s comment: Prof. James Drife: Adjuvanted vaccines in pregnancy: are they safe?
    Pregnant women were one of the high-risk groups for whom vaccination was recommended in the “swine flu” pandemic of 2009. The vaccine used in The Netherlands contained an adjuvant to boost the immune response. Information on its safety was limited to showing a lack of teratogenesis, but the immune response affects placentation throughout pregnancy. This case-control study of pre-eclampsia and intra-uterine growth restriction in 2010 provides reassurance that neither condition was associated with the adjuvanted vaccine.

    Adjuvanted vaccines in pregnancy: no evidence for effect of the adjuvanted H1N1/09 vaccination on occurrence of preeclampsia or intra-uterine growth restriction

    Alies Coenders, Nienke K. Koopmans, Kim Broekhuijsen, Henk Groen, Janna M.A. Karstenberg-Kramer, Kim van Goor, Mariette Groenewout, Aren J. van Loon, Marijke M. Faas, Maria G. van Pampus

    European Journal of Obstetrics & Gynecology and Reproductive Biology, pages 14 - 19

  • Editor’s comment: Prof. James Drife:  Off-label prescribing in pregnancy: time for action
    Pharmaceutical companies may be reluctant to apply for a product to be licensed for use in pregnancy. This has two results. Effective medications are now being prescribed “off-label”, and women are being denied optimal treatment because some doctors are apprehensive about prescribing it. This important Editorial calls for urgent action on this long-standing problem. Professional societies have an important role, and the Editorial is accompanied by a review from the French College on the off-label use of misoprostol in obstetrics and gynecology.

    Off-label prescribing in pregnancy—a case of risky business or business as usual?

    Luke E. Grzeskowiak, Ben W. Mol

    European Journal of Obstetrics & Gynecology and Reproductive Biology, pages 78 - 79

Pages

E-Alert

Subscribe to our E-Alert to stay informed of all new content as it's published on this platform.


Share


News

Commentaries by Editor Prof. Jim Thornton

Obstetrics Resource Centre introduction


About the Editors

  • James O. Drife

    James Drife is Emeritus Professor of Obstetrics and Gynaecology at the University of Leeds, UK. He has written widely on...
  • Jim Thornton

    Jim Thornton is Professor of Obstetrics and Gynaecology, at Nottingham University, and deputy director of the Nottingham Clinical Trials Unit...